ArticleCureus2025
Impact of Long-Term Glucocorticoid Therapy on the Response to Biologic Agents in Rheumatoid Arthritis: A Prospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Prolonged glucocorticoid use remains common in rheumatoid arthritis (RA), particularly in resource-limited settings. However, long-term exposure may reduce the effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) and increase the risk of metabolic and skeletal complications. This prospective observational study evaluated the association between cumulative glucocorticoid dose and clinical response to biologic therapies in patients with RA. Methodology Adults with RA fulfilling the 2010 ACR/EULAR classification criteria and treated with biologic therapy were prospectively included. Sociodemographic data, disease duration, Disease Activity Score in 28 joints (DAS28), radiographic erosions, inflammatory markers, background and concomitant therapies, and major cardiometabolic and skeletal comorbidities were recorded. Glucocorticoid exposure was analyzed according to treatment duration and cumulative prednisone-equivalent dose. Treatment effectiveness and safety were assessed at 6 and 12 months. Results A total of 153 patients were included, predominantly women (75.8%), with a mean age of 57.5 ± 13.7 years and a mean RA duration of 15.2 ± 9.3 years. At baseline, 70.6% were receiving glucocorticoids. Compared with non-exposed patients, glucocorticoid-exposed patients had higher disease activity (mean DAS28-CRP: 4.08 vs 3.09; p = 0.019), a less favorable clinical response at 12 months (DAS28-CRP: 3.92 vs 2.92; p = 0.005), and more radiographic erosions (74.0% vs 35.5%; p = 0.008). The effectiveness of anti-TNF and anti-IL-6 therapies decreased with increasing cumulative glucocorticoid dose, with no good clinical response observed beyond 20,000 mg, whereas response was partially preserved with Janus kinase (JAK) inhibitors (20%) and rituximab (25%). Diabetes (relative risk [RR] = 4.05), hypertension (RR = 4.02), and osteoporosis (RR = 2.48) were more frequent in glucocorticoid-exposed patients. Conclusions Prolonged glucocorticoid exposure in RA was associated with a lower likelihood of achieving a good clinical response to biologic therapies targeting cell surface receptors and with higher rates of metabolic and skeletal complications. These real-world data support rational, time-limited glucocorticoid use and careful selection of biologic class in patients with high cumulative exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.